Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.

MLA

Sen, Taha, et al. “Sodium Glucose Co-Transporter 2 Inhibition Increases Epidermal Growth Factor Expression and Improves Outcomes in Patients with Type 2 Diabetes.” Kidney International, vol. 104, no. 4, Oct. 2023, pp. 828–39. EBSCOhost, https://doi.org/10.1016/j.kint.2023.07.007.

APA

Sen, T., Ju, W., Nair, V., Ladd, P., Menon, R., Otto, E. A., Pyle, L., Vigers, T., Nelson, R. G., Arnott, C., Neal, B., Hansen, M. K., Kretzler, M., Bjornstad, P., & Heerspink, H. J. L. (2023). Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes. Kidney International, 104(4), 828–839. https://doi.org/10.1016/j.kint.2023.07.007

Chicago

Sen, Taha, Wenjun Ju, Viji Nair, Patricia Ladd, Rajasree Menon, Edgar A Otto, Laura Pyle, et al. 2023. “Sodium Glucose Co-Transporter 2 Inhibition Increases Epidermal Growth Factor Expression and Improves Outcomes in Patients with Type 2 Diabetes.” Kidney International 104 (4): 828–39. doi:10.1016/j.kint.2023.07.007.